Will Sarepta Therapeutics (SRPT) stock recover?
What do analysts say about SRPT?
Average price target from 5 analysts: $27 over ~12 months (Hold consensus), i.e. +25 % from the current price. Most reliable firm on SRPT: Credit Suisse (90% hit rate, 10 scored calls). A target is a 12-month view, not for tomorrow.
What happened after its past drops?
Over 2013-2026, Sarepta Therapeutics saw 9 drops of 30%+. Twelve months later it was +26 % on median (positive 67% of the time). It regained its pre-crash high in 78% of cases, in about 15 months. (monthly history 2013-2026 — transparency data, not a guarantee)
SRPT's biggest months
⚠️ Drop measured from the 12-month high; analyst targets on a ~12-month horizon; monthly history since 2013. Information, not investment advice. Past performance does not guarantee future results.
Frequently asked questions
Will Sarepta Therapeutics stock recover?
No one can guarantee it, and we won't. What we know: it's down 38 % from its high; analysts target $27 over 12 months (+25 % from the current price). Over 2013-2026, Sarepta Therapeutics saw 9 drops of 30%+. Twelve months later it was +26 % on median (positive 67% of the time). It regained its pre-crash high in 78% of cases, in about 15 months. Past performance does not guarantee future results.
Why has SRPT dropped so much?
We don't assert the cause of a drop — a headline can be a consequence or a coincidence. What we measure is what comes next: the analysts' target and the stock's historical behavior after this kind of drop.
Should I buy SRPT now that it's down?
A drop is not a buy signal by itself. Cross-check with the analysts' target, their real reliability on the stock (most solid: Credit Suisse, 90% hit rate), and the fundamentals. This is not personalized advice.